Company news

Biomea Fusion, Inc. news in 2024

Biomea Fusion, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

December 16, 2024

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

December 15, 2024

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

December 11, 2024

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

December 8, 2024

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

December 5, 2024

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

October 29, 2024

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

October 28, 2024

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

October 20, 2024

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

September 30, 2024

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

September 25, 2024

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

July 30, 2024

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

June 5, 2024

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

May 29, 2024

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

May 1, 2024

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 30, 2024

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

March 31, 2024

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

March 31, 2024

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

January 8, 2024

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

January 7, 2024

Decks in 2024